SCHEMBL6009577

SCHEMBL6009577

O=C(c1ccoc1)c1ccc2[nH]c(=O)cc(-c3cccc(Cl)c3)c2c1

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.49
KMT2A Q03164 1/20 0.49
RXFP1 Q9HBX9 1/20 0.49
FNTA P49354 3/20 0.42
FNTB P49356 3/20 0.42
CHEK1 O14757 1/20 0.41
WEE1 P30291 1/20 0.41
NUDT1 P36639 5/20 0.39
CA12 O43570 1/20 0.37
CA9 Q16790 1/20 0.37
HPGD P15428 1/20 0.36
MAPK1 P28482 1/20 0.36
HTT P42858 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
JAK2 O60674 1/20 0.36
BTK Q06187 1/20 0.36
ALOX5 P09917 1/20 0.36
EGFR P00533 1/20 0.36
LMNA P02545 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1538310 0.86 MEN1 (0.59) MEN1KMT2ARXFP1FNTAFNTB
SCHEMBL5657749 0.83 MEN1 (0.52) MEN1KMT2ARXFP1FNTAFNTB
SCHEMBL5657976 0.82 MEN1 (0.51) MEN1KMT2ARXFP1FNTAFNTB
SCHEMBL5656275 0.80 MEN1 (0.48) MEN1KMT2ARXFP1FNTAFNTB
SCHEMBL5027012 0.78 LTB4R (0.37) NUDT1CA12CA9
SCHEMBL7205333 0.78 MEN1 (0.49) MEN1KMT2ARXFP1FNTAFNTB
SCHEMBL5550240 0.78 MEN1 (0.49) MEN1KMT2ARXFP1FNTAFNTB
SCHEMBL6010190 0.78 FNTA (0.47) KMT2AFNTAFNTB
SCHEMBL5722642 0.76 MEN1 (0.52) MEN1KMT2ARXFP1FNTAFNTB
SCHEMBL5780432 0.76 RXFP1 (0.52) MEN1KMT2ARXFP1FNTAFNTB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7067531-B2 Farnesyl transferase inhibiting 6-heterocyclylmethyl quinolinone derivatives JANSSEN PHARMACEUTICA N.V. (BE) 2006-06-27 US disclosed
US-20030199547-A1 Farnesyl transferase inhibiting 6-heterocyclylmethyl quinolinone derivatives JANSSEN-CILAG S.A. (FR) 2003-10-23 US disclosed
EP-1322644-A1 FARNESYL TRANSFERASE INHIBITING 6-HETEROCYCLYLMETHYL QUINOLINONE DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 2003-07-02 EP disclosed
WO-2002024687-A1 FARNESYL TRANSFERASE INHIBITING 6-HETEROCYCLYLMETHYL QUINOLINONE DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 2002-03-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030199547-A1 Farnesyl transferase inhibiting 6-heterocyclylmethyl quinolinone derivatives FNTA, FNTB, RCE1 MEN1 1698/4885KMT2A 2978/4885RXFP1 2536/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.